Jump Financial LLC Grows Position in 10x Genomics $TXG

Key Points

• Jump Financial LLC increased its holdings in 10x Genomics by 144.3% in the 1st quarter, owning 452,282 shares valued at $3,948,000 at the quarter's end.
• 10x Genomics reported a revenue of $172.91 million in its last quarter, surpassing analyst estimates of $139.36 million, along with earnings of $0.28 per share.
• Research analysts have mixed ratings for the stock, with consensus indicating a Hold rating and a target price of $13.54.

Jump Financial LLC increased its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 144.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 452,282 shares of the company's stock after acquiring an additional 267,181 shares during the quarter. Jump Financial LLC owned approximately 0.37% of 10x Genomics worth $3,948,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. AlphaQuest LLC lifted its stake in 10x Genomics by 8.3% in the first quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock worth $257,000 after acquiring an additional 2,258 shares during the period. EntryPoint Capital LLC bought a new position in 10x Genomics in the first quarter worth about $420,000. Fox Run Management L.L.C. bought a new position in 10x Genomics in the first quarter worth about $270,000. Russell Investments Group Ltd. raised its holdings in 10x Genomics by 385.6% in the first quarter. Russell Investments Group Ltd. now owns 81,669 shares of the company's stock worth $713,000 after purchasing an additional 64,851 shares in the last quarter. Finally, Nuveen LLC bought a new position in 10x Genomics in the first quarter worth about $1,755,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Adam Taich sold 22,315 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,149 shares of company stock worth $539,865. 10.03% of the stock is owned by company insiders.

10x Genomics Stock Down 1.9%

Shares of TXG traded down $0.27 during mid-day trading on Friday, hitting $14.01. 1,566,109 shares of the company traded hands, compared to its average volume of 3,022,419. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $24.76. The company has a market capitalization of $1.74 billion, a PE ratio of -20.01 and a beta of 2.00. The business has a 50 day moving average of $12.92 and a 200 day moving average of $10.68.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the prior year, the company posted ($0.32) earnings per share. The company's revenue for the quarter was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, research analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TXG. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a "hold" rating in a report on Friday, August 8th. Bank of America boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 9th. UBS Group boosted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Finally, Barclays restated an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $13.54.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.